SPDR S&P Biotech (XBI) 231.87 $XBI Zacks Investment

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 2:33 PM

SPDR S&P Biotech (XBI) 231.87 $XBI

Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 8:30AM CDT
Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF
BIIB: 421.15 (+7.80), BBC: 33.99 (+0.54), BIB: 168.25 (+7.38), XBI: 231.84 (+3.41), AMGN: 162.10 (+7.84)

Advances in Technology, Biotech Changing Humans' Relationship to the Environment
at The Street - Sat Mar 14, 5:05AM CDT
Steve Gullans, co-author of 'Evolving Ourselves,' says technology and biotechnology are creating a world of unnatural selection for humans.
QQQ: 106.43 (+1.09), XBI: 231.84 (+3.41), XLK: 41.88 (+0.39), IBB: 353.29 (+7.96)

3 Biotech ETFs Crushing The Market In 2015
Zacks Funds - Seeking Alpha - Fri Mar 13, 3:16PM CDT
As anyone in the biotech investing space can tell you, picking winners in this corner of the healthcare market can be extremely difficult. Failed trials, FDA concerns, and pricing issues have hit a number of companies in this sector lately, turning...
BBC: 33.99 (+0.54), BIB: 168.25 (+7.38), XBI: 231.84 (+3.41)

3 Biotech ETFs Crushing the Market in 2015 - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Fri Mar 13, 11:02AM CDT
If you are looking for impressive biotech funds consider this trio, as all of its members have gained more than 20 percent so far this year.
BIIB: 421.15 (+7.80), BBC: 33.99 (+0.54), BIB: 168.25 (+7.38), XBI: 231.84 (+3.41), IBB: 353.29 (+7.96), AMGN: 162.10 (+7.84)

SPDR S&P Biotech ETF Shares Up 44.6% Since SmarTrend's Buy Recommendation (XBI)
Comtex SmarTrend(R) - Fri Mar 13, 9:23AM CDT
SmarTrend identified an Uptrend for SPDR S&P Biotech ETF (AMEX:XBI) on October 17th, 2014 at $158.01. In approximately 5 months, SPDR S&P Biotech ETF has returned 44.65% as of today's recent price of $228.55.
XBI: 231.84 (+3.41)

The Biotech Bubble Debate: Solid Science vs. Sky-High Valuations
at The Street - Thu Mar 12, 8:25AM CDT
Biotech companies are experiencing an unprecedented run of scientific success, but biotech stock valuations have never been more expensive.
XBI: 231.84 (+3.41), AAPL: 124.35 (+0.76)

Biotech ETFs Head To Head: XBI Vs. FBT
Zacks Funds - Seeking Alpha - Thu Mar 12, 7:15AM CDT
After a blockbuster 2014, the healthcare space continues its strong performance this year thanks to strong earnings growth, a merger and acquisition frenzy, corporate deals, and encouraging industry trends. While pharma stocks are flying higher,...
FBT: 123.82 (+2.95), XBI: 231.84 (+3.41)

Biotech ETFs Head to Head: XBI Vs. FBT - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 11, 10:11AM CDT
Investors seeking to tap the encouraging trends in the biotech sector should take a look to the two best performing ETFs and their key differences.
FBT: 123.82 (+2.95), XBI: 231.84 (+3.41)

Biotechnology Boom
Young Money Monsters - at Seeking Alpha - Tue Mar 10, 4:48AM CDT
Editor's note: Originally published on March 6, 2015 by Jacob Urban Biotechnology has been the topic of many investment conversations of late, and as of now there might not be a hotter sector. Despite the rise in biotechnology over the past...
BBP: 31.90 (+0.33), PBE: 57.18 (+1.01), BIIB: 421.15 (+7.80), SBIO: 30.86 (+0.45), BBC: 33.99 (+0.54), GILD: 101.39 (+1.78), FBT: 123.82 (+2.95), XBI: 231.84 (+3.41), BBH: 133.68 (+3.37), AMGN: 162.10 (+7.84), CELG: 120.64 (+2.91)

Women in ETFs Helping to Propel Careers and Industry Higher
at The Street - Mon Mar 09, 3:07PM CDT
Joanne Hill, the co-founder of Women in ETFs, describes the industry landscape and how the organization is designed to inspire and advance both careers and the industry to new highs.
XLB: 49.55 (-0.29), EWG: 29.98 (+0.79), XBI: 231.84 (+3.41), XLY: 75.87 (+0.71), EWQ: 25.76 (+0.42), IBB: 353.29 (+7.96), XLU: 44.20 (+0.72), TLT: 127.82 (+1.10), XRT: 99.46 (+0.54), XLV: 73.28 (+1.47), XLP: 48.67 (+0.39), SPY: 208.06 (+2.23), QQQ: 106.43 (+1.09), EWU: 18.09 (+0.20), DIA: 179.39 (+1.83), XLK: 41.88 (+0.39), IWM: 123.56 (+0.95), XLF: 24.59 (+0.27), XLE: 75.08 (+0.45)

NASDAQ Hits 5,000: Does The IPO Market Suggest A Biotech Bubble?
Renaissance Capital IPO Research - Seeking Alpha - Tue Mar 03, 8:07AM CST
The NASDAQ Composite is fast approaching its all-time high from March 2000. On Monday it reached 5,000 for the first time since the tech bubble. Today's technology IPOs look much tamer in number than they did 15 years ago, but a boom in biotech...
QQQ: 106.43 (+1.09), XBI: 231.84 (+3.41), IBB: 353.29 (+7.96)

3 ETFs Surging at Start of 2015 - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 10:19AM CST
These funds have provided solid returns in the year-to-date frame beating the broad U.S. equity market return.
PXE: 28.25 (+0.10), SPY: 208.06 (+2.23), XBI: 231.84 (+3.41), XSD: 89.26 (+1.10)

All That Cash
Derek Lowe - Seeking Alpha - Wed Feb 25, 1:12PM CST
From the LifeSciVC blog, here's a revealing comparison of the amount of money going into startups in this business. This is why I tend to get worked up about the number of stock buyback plans among the big pharma players. It would seem that...
XBI: 231.84 (+3.41), IBB: 353.29 (+7.96)

Biotech Weekly: 5 Factors Contributing To The Crazy Week That Was In Small Cap Biotech
Daniel Ward - at Seeking Alpha - Mon Feb 23, 7:40AM CST

HEB: 0.23 (unch), XBI: 231.84 (+3.41), IBIO: 0.81 (+0.12), IBB: 353.29 (+7.96), SPPI: 6.17 (-0.07), CLTX: 0.88 (+0.01)

Top Funds' Activity In Q4 2014
Leo Kolivakis - Seeking Alpha - Fri Feb 20, 2:04PM CST
Svea Herbst-Bayliss and Sam Forgione of Reuters report, Top U.S. hedge funds cut Apple stakes ahead of all-time high : Top U.S. hedge fund management firms, including David Einhorn's Greenlight Capital and Philippe Laffont's Coatue Management,...
HK: 1.57 (-0.08), XLB: 49.55 (-0.29), GREK: 10.65 (-0.03), XBI: 231.84 (+3.41), IBB: 353.29 (+7.96), NBG: 1.28 (+0.05), RRC: 45.70 (+0.41), RIG: 13.78 (+0.18), XLK: 41.88 (+0.39), SPR: 51.05 (+0.50), TWTR: 46.45 (-0.21), AAPL: 124.35 (+0.76), CSCO: 28.26 (+0.32), BHI: 59.47 (+0.60), XLE: 75.08 (+0.45), DVN: 58.22 (+0.52), FEYE: 42.22 (+0.18), XEC: 106.43 (-0.32), GSG: 19.09 (-0.23), NFLX: 421.30 (-17.10), GENE: 4.45 (-0.26), ROSG: 3.33 (-0.03), SBIO: 30.86 (+0.45), QQQ: 106.43 (+1.09), IDRA: 4.27 (+0.12), IWM: 123.56 (+0.95), BABA: 83.72 (+1.86)

SPDR S&P Biotech ETF Up 32.7% Since SmarTrend Uptrend Call (XBI)
Comtex SmarTrend(R) - Thu Feb 19, 9:40AM CST
SmarTrend identified an Uptrend for SPDR S&P Biotech ETF (AMEX:XBI) on October 17th, 2014 at $158.01. In approximately 4 months, SPDR S&P Biotech ETF has returned 32.74% as of today's recent price of $209.73.
XBI: 231.84 (+3.41)

SPDR S&P Biotech ETF Set to Possibly Pullback After Yesterday's Rally of 1.64%
Comtex SmarTrend(R) - Tue Feb 17, 4:30PM CST
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $203.54 to a high of $208.04. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $203.42 on volume of 755,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 231.84 (+3.41)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Paris Baguette Opens New Café in Novato, CA

Another Feather in Paris Baguette’s Cap Alright, as far as pastry shops go, Paris Baguette is rolling out those cinnamon rolls like they're planting flags on the moon. They've just added a new café in Novato, California, bringing the artisanal charm of their iconic baked goods to yet another American doorstep. A Local Affair with Big Aspirations The man of the hour,...

Will Hair Loss Drugs Challenge Transplant Clinics?

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

Navigating Roof Damage Insurance Claims: Key Insights

No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...

KeyCorp Plans Redemption of Series E Preferred Stock

KeyCorp Drops a Major Redemption Bombshell Out of the blue, KeyCorp (NYSE: KEY) just tossed a curveball at investors with the announcement they’re redeeming every last one of their Series E Fixed-to-Floating Rate Perpetual Non-Cumulative Preferred Stock shares come December 15, 2026. This move is bound to stir the pot a bit even if you’ve been around the block a few...

Honoring Boston's Architects Changing the Game

Celebrating Architecture's Influencers in Boston Every now and then, a profession needs a wake-up call. Stirring the pot, shaking the roots, call it what you will, but when folks rally together with a shared vision, change doesn't just seem possible — it's inevitable. On November 12, the Boston Society of Architects (BSA) and Architecture in Common (AiC) did just that...

SOCSA: The Future of Safety in Confined Spaces?

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...